Medical Condition

breast neoplasms

Total Trials

12

Recruiting Now

12

Trial Phases

Phase 2, Phase 3, Phase 1

ClinicalMetric tracks all active clinical trials for breast neoplasms sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — breast neoplasms Clinical Trials

How many clinical trials are currently recruiting for breast neoplasms?

ClinicalMetric currently tracks 12 actively recruiting clinical trials for breast neoplasms, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 12. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for breast neoplasms?

breast neoplasms research spans Phase 1 (1 trial), Phase 2 (4 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a breast neoplasms clinical trial?

Eligibility criteria for breast neoplasms trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Merck Sharp & Dohme LLC 2 trials

Fujian Cancer Hospital 2 trials

Hunan Cancer Hospital 1 trial

Kristina A. Fanucci 1 trial

Hubei Cancer Hospital 1 trial

Recruiting Clinical Trials

NCT05326295

Recruiting

Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients

Hunan Cancer Hospital

View Trial →

NCT07222215 Phase 2

Recruiting

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without Diarrhea

Hubei Cancer Hospital

View Trial →

NCT06312176 Phase 3

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Enrollment

1,200 pts

Location

United States, Argen...

Sponsor

Merck Sharp & Dohme LLC

View Trial →

NCT06421285

Recruiting

Effect of Preoperative Exercise on the Prevention of Secondary Lymphedema in Breast Cancer Patients

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer

Fujian Cancer Hospital

View Trial →

NCT05485766 Phase 2

Recruiting

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Enrollment

2,400 pts

Location

United States, Argen...

Sponsor

Merck Sharp & Dohme LLC

View Trial →

NCT07581834 Phase 2

Recruiting

Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study

Fujian Cancer Hospital

View Trial →

NCT06121557 Phase 1

Recruiting

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Sun Yat-Sen Memorial Hospital ...

View Trial →

NCT06464913 Phase 2

Recruiting

Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction

Second Affiliated Hospital, Zh...

View Trial →

NCT07595718

Recruiting

AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases

Related Conditions

breast cancer (2) hormone receptor positive breast cancer (2) hr her2 breast cancer (2) triple negative breast neoplasms (2) neoplastic cells circulating (1) chemotherapy effect (1) estrogen receptor positive breast cancer (1) metastatic breast cancer (1) human epidermal growth factor 2 negative carcinoma of breast (1) her2 breast cancer (1) esr1 gene mutation (1) er wildtype (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology